30 January 2013 06:53 [Source: ICIS news]
SINGAPORE (ICIS)--Swiss pharmaceuticals firm Roche posted on Wednesday a 2% year-on-year increase in its 2012 net profit to Swiss francs (Swfr) 9.77bn ($10.6bn), with sales partly boosted by growing demand for its cancer medicines.
The company also benefited from the weakening of the Swiss franc against the dollar and the Japanese yen, it said.
On a constant exchange rate basis, the company’s net profit rose by 1% year on year in 2012, the company said in a statement.
The company’s group sales rose by 7% year on year to Swfr45.5bn in 2012. On a constant exchange rate basis, group sales rose by 4%.
The company’s core operating profit was up by 13% year on year at Swfr17.2bn in 2012. On a constant exchange rate basis, its core operating profit was up by 11%.
“Roche expects group sales in 2013 to increase in line with the sales growth recorded in 2012 at constant exchange rates,” it added.
($1 = Swfr0.92)
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections